Professional
Added to YB: 2025-05-08
Pitch date: 2025-05-06
PLSE [bearish]
Pulse Biosciences, Inc.
+14.22%
current return
Author Info
White Diamond Research is a small cap research firm (often short). Sign up for the newsletter.
Company Info
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians.
Market Cap
$1.1B
Pitch Price
$16.60
Price Target
N/A
Dividend
N/A
EV/EBITDA
-19.15
P/E
-18.08
EV/Sales
N/A
Sector
Health Care Equipment and Supplies
Category
turnaround
An Industry Expert’s Analysis of Pulse Biosciences Suggests That Its Pivot Into Benign Thyroid Ablation Will Be Another Dead End
PLSE short: 20yr journey with NPS tech shows repeated failures & pivots from oncology to dermatology to cardiac PFA, now thyroid ablation. Industry expert Dr. Reddy (owns PLSE stock) states no advantage of nano vs micro-pulse PFA. Early thyroid data weak (83% reduction vs 95.7% for RF). Small market (~$10-20M), 3 CEO changes in 3yrs. $1B+ valuation unjustified.
Read full article (13 min)